1 / 73

Infectious Diarrhea

Infectious Diarrhea. ID Fellows Course July 2, 2010 Frederick S. Buckner, MD. Global mortality from selected infectious diseases. *WHO 2002. Intestinal Fluid Balance:. Site L In / L Out Efficiency Jejunum 9-10/4-5 50% Ileum 4-5/3-4 80% Colon 1.5/1.4 95%

bailey
Télécharger la présentation

Infectious Diarrhea

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Infectious Diarrhea ID Fellows Course July 2, 2010 Frederick S. Buckner, MD

  2. Global mortality from selected infectious diseases *WHO 2002

  3. Intestinal Fluid Balance: SiteL In / L OutEfficiency Jejunum 9-10/4-5 50% Ileum 4-5/3-4 80% Colon 1.5/1.4 95% Stool 100-200 ml 98-99% Diarrhea occurs when reabsorption decreases to around 95-96%; minor changes result in major fluid losses

  4. FIC-NIH

  5. Pathogenic mechanisms • Toxins: • Preformed: Staphylococcus aureus, Clostridium perfringens, Bacillus cereus • Formed in the intestine by ingested bacteria: • Stimulate intestinal secretion: Vibrio cholerae, enterotoxigenic E. coli • Cytotoxins: Clostridium difficile, Shigella, enterohemorrhagic E. coli • Invasion: Shigella, Salmonella, Campylobacter, Yersinia • Disruption of enterocytes leading to decreased absorption: Giardia, Cryptosporidium

  6. Is the pathology in the small bowel or colon?

  7. Agents of diarrhea based on localization within the intestine

  8. Important agents of infectious diarrhea

  9. www.staceysstuff.com/ images/diarrhea.jpg

  10. Case 1 • A 72 y/o man with Alzheimer’s disease is sent to the Emergency Room from his nursing home for evaluation of lethargy and fever. He has been incontinent of stool for 2-3 days and his attendants have started using diapers on him. The patient has a history of recurrent UTIs. Exam: T102°, BP 100/60, HR 120, RR24. Abd: moderate tenderness. Rectal: no masses, heme +

  11. Clostridium difficile Anaerobic spore forming bacillus

  12. Coloured transmission electron micrograph of Clostridium difficle forming an endospore (red) Dr Kari Lounatmaa/Science Photo Library

  13. Clostridium difficile colitis Normal colon Pseudomembranous colitis

  14. Overview • Epidemiology of C. difficile infections • Emergence of more virulent strains • Pathogenesis • Clinical spectrum • Diagnostic tests • Management • Fulminant cases • Recurrences • New treatments • Infection control

  15. Frequency of CDAD. Mortality from CDAD.

  16. Annual Incidence (per 100,000 Population) of C. difficile Infection in Sherbrooke, Quebec, 1991–2003 Kelly C, LaMont J. N Engl J Med 2008;359:1932-1940

  17. University of WashingtonC. difficile cases 2008-2010 Health Care + Community acquired Health Care acquired *2008: includes pts with + results after 48 hours **After 2008: Includes pts with + results after 72 hours

  18. C. difficile-associated disease:what’s changing? • Geographic spread of “epidemic” strains • Appearance of strains with increased virulence (?) • Spread of disease into “low risk” populations • Emergence of fluoroquinolones as a major risk factor for CDAD • Increasing failure rate with metronidazole therapy

  19. Recent reports

  20. Fulminant CDAD(Pittsburgh Hospital) 1989-992000 • CDAD rate 6.8 11.6 (rate/1,000 admissions) • Fulminant cases 1.6% 3.2% • Colectomies* 2.7/year 17/year *Recent surgery, immunosupression, and prior CDAD were common predisposing conditions Dallal RM, et al. Ann Surg 2002;235:363

  21. Epidemic strain • Emerged 2000-2003 • NAP1/027, REA Group BI / Toxinotype III • Previously an uncommon strain • First recognized in the 1980’s • Increased toxin production: • Toxin A: 16X • Toxin B: 23X • Binary toxin: unknown significance • Uniformly quinolone resistant in vitro Recent review on B1/NAP1/027 strain: Gastroenterology 136:1913, 2009

  22. States that have had > 1 hospital that has reported CDI caused by the B1/NAP1/027 epidemic strain as of October, 2008 (red).

  23. Clostridium difficileReservoirs (asymptomatic carriage) • 15-70% of healthy neonates (C. diff was discovered in 1933 during a study of the intestinal biota of newborns) • 3-8% of healthy adults • 7-14% of elderly hospital patients • Up to 18% of pregnant women have vaginal colonization

  24. Pathogenesis Asymptomatic C. difficile colonization Antimicrobial C. difficile exposure C. difficile-associated diarrhea Hospitalization Modified from: Johnson S,Gerding DN. Clin Infect Dis. 1998;26:1027-1036

  25. 50 40 30 20 10 0 0 1 2 3 4 Clostridium difficile acquisition is correlated to duration of hospitalization Percentage of patients who acquired c. difficile >4 <1 3-4 1-2 2-3 Length of hospital stay (wks) Johnson and Gerding J Infect Dis 1998; 26:1027

  26. Clostridium difficile diarrhea is toxin-mediated • Large clostridial toxins (LCTs): Large (>250 kDa), single-unit proteins which glycosylate small GTP-binding proteins (Rho, Ras) involved in cell cytoskeleton organization • Toxin A ‘enterotoxin’ • Toxin B ‘cytotoxin’ • Both toxins are pathogenic* *Lyras D et al. Nature 458:1176, 2009

  27. Normal Cytotoxic Effect

  28. Histopathology of CDAD Normal colon brush border Necrotic colon brush border (CDAD)

  29. Clinical Spectrum ofClostridium difficile Infections Syndrome Frequency • Asymptomatic colonization +++++++++ • Diarrhea (+ PMC) ++ • Pseudomembranous colitis + • Severe ileus/ Fulminant colitis <+

  30. Antimicrobial agents that may induce CDAD • Antineoplastic agents have also been associated with CDAD: • Doxorubicin, cisplatin, cyclophosphamide, methotrexate, chlorambucil

  31. Clostridium difficileRisk Factors • Additional risk factors in hospitalized pts. • Advanced age • Severity of underlying illness • Disruption of normal intestinal motility: enemas, stool softeners, pro-motility agents • PPIs (although spores are acid resistant. May be a marker of co-morbidity). • Adverse prognostic factors • Peak WBC > 20,000 (RR 4.8) • Peak creatinine > 2 (RR 3.1)

  32. Clostridium difficileClinical • Usually occurs after 5-10d of antibiotic Rx, but range from 1-70+ days • Diarrhea may range up to “cholera-like” • Fever: 30-50% • Mean peripheral WBC 15-16,000; 25% may have WBC > 35,000 • May present w/ toxic megacolon or acute abdomen without diarrhea, particularly in patients on opiates, anti-motility agents, or post GI-surgery • Case fatality rate ~2-3%

  33. Antibiotic associated diarrhea DDX Only 10-20% of AAD is due to C. difficile

  34. C. difficile disease diagnosis

  35. Toxic megacolon

  36. Pseudomembranous colitis “Accordion Sign”

  37. The d-zone, vol 37, 2008 http://uw.prnrx.org/therapyTopics.asp

  38. C. difficile testing at UWMC + HMCOrder: “Stool for C.difficile testing.” #1 Formed stool samples will be rejected #2 PCR for Toxin B gene* + C. difficile disease *Sensitivity: 98.8%, Specificity: 90.8%

  39. Previous C. difficile testing at UWMC + HMC #1 • C. difficile antigen assay (EIA) • Very sensitive (97%), not specific for disease • >95% negative predictive value + - #2 - • Combo-tox (A/B) testing (EIA) • >95% specificity #3 PCR for Toxin B gene + + - C. difficile disease Negative for C. difficile

  40. CDAD:Appropriate Testing • Only re-test after negative PCR if pre-test suspicion is VERY high • No need to order stool tests in triplicate! • No need to test for cure… pt comes out of precautions if diarrhea is gone and 7 days of treatment under his / her belt!

  41. CDAD:Treatment Basics • STOP the offending abx (if possible) • START anti-C.diff therapy as soon as you start to rule out CDAD (unless pt looks clinically great, in which case you could consider waiting for testing to come back). • AVOID anti-motility drugs.

  42. Clostridium difficileTreatment (circa 2005)

  43. Response Rates to Vancomycin and Metronidazole Therapy, According to the Severity of C. difficile Infection ≥ 2 points = Severe 1 point: Age > 60 Temp >101 F Albumin < 2.5 mg/dL WBC >15K 2 points: PMC at colonoscopy ICU patient Kelly C, LaMont J. N Engl J Med 2008;359:1932-1940

  44. Request imaging (Abd CT) and obtain surgery consult if evidence for toxic megacolon Cohen SH et al. Infection Control and Hospital Epidemiology. May, 2010

  45. Clostridium difficileTreatment: Special Situations • When to operate?? • Strong indications: • Megacolon • Prolonged and (?) irreversible ileus • Perforation • Mortality rates (in reported series) of cases requiring surgery range from 30 to > 50%. Are we waiting too long??

  46. Equivalent response rates of low dose and high-dose vancomycin Lefler DA and Lamont JT. Gastroenterology 136:1899, 2009

  47. CDAD:Treatment Pearls • Switch from metro to PO vanco if pt deteriorates, or if no improvement in first 3 days of therapy. • No role for IV vanco. • In SEVERE, COMPLICATED disease, you may combine IV metro with PO vanco (PR if ileus). • No tapering for first episode.

  48. Recurrent C. difficile Diarrhea • Occurs 6-25% • Retreat first-time recurrences with the same regimen used to treat the initial episode (usually MTZ) • Risk of subsequent episode in patients who already have had a recurrence: 45% • Antibiotic resistance not a factor in relapse

More Related